Group 1 - The core viewpoint of the article is that MicroTech Medical-B (02235.HK) expects significant revenue growth and a turnaround in net profit by the end of 2025, projecting revenue of at least RMB 650 million, which represents a year-on-year increase of approximately 88.1% [1] - The company anticipates a net profit attributable to the parent company of no less than RMB 38 million for the fiscal year 2025, a substantial improvement compared to a net loss of RMB 63.1 million in 2024, indicating a growth of RMB 101.1 million [1] - As of February 26, 2026, MicroTech Medical-B's stock closed at HKD 7.45, reflecting a 0.27% increase with a trading volume of 26,800 shares and a turnover of HKD 199,700 [1] Group 2 - The stock is primarily rated as "strong buy" by investment banks, with one bank issuing a strong buy rating in the last 90 days and a target average price of HKD 13.7 [1] - Huachuang Securities has recently provided a strong buy rating for MicroTech Medical-B, setting a target price of HKD 13.7 [1] - The market capitalization of MicroTech Medical-B is HKD 1.231 billion, ranking 18th in the medical device II industry [1]
微泰医疗-B(02235.HK)发盈喜 预计2025年度归母净利润不低于3800万元